Építés alatt – nem éles oldal
Belépés
Még nem keres résztvevőt itt: Egyesült Államok4. fázis

The TRIBECA Study (TRIessence/Byqlovi for Easier CAtaract Surgery)

A legfontosabb adatok

Ki végzi
Research Insight LLC
Hol
Laguna Hills (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Toborzás még nem indult
Fázis
4. fázis
Résztvevők
40 fő, tervezett
Kezdés
2026. ápr. 1.
Várható befejezés
2027. jan. 31.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • Triamcinolone (Optional)
  • control group
A regiszteradat frissítve
2026. március 31.

Ki vehet részt

Életkor
22 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 38 feltétel megnézéseKevesebb

Ki vehet részt

  • A male or female subject in good general health, > 22 years of age at the time of the screening visit
  • A subject must be able to comprehend and willing to give informed consent
  • A woman of child-bearing potential must not be pregnant or lactating
  • A subject has the availability, willingness and sufficient cognitive awareness to comply with exam procedures and able to return for all scheduled study visits
  • A subject with a cataract for which routine phacoemulsification extraction and implantation of an intraocular lens has been planned
  • A subject with clear ocular media other than cataract in their scheduled operative eye
  • A subject with normal OCT of the macula in both eyes
  • A subject has the potential for a post-operative Snellen BCDVA of 20/30 or better in both eyes

Ki nem vehet részt

  • A subject with a known sensitivity to any of the study medications
  • A subject with a history as a steroid responder or glaucoma
  • A subject with a known pathology that may affect visual acuity (as determined by the Investigator); particularly retinal changes that affect vision (macular degeneration, cystoid macular edema, proliferative diabetic retinopathy, etc.) in their scheduled surgical eye
  • A subject that has undergone prior intraocular surgery in the scheduled surgical eye within the last 6 months or laser surgery within three months prior to screening
  • A subject that requires the use of systemic or ocular medications that may affect vision, ocular inflammation or pain
  • A subject currently participating or has participated in another clinical trial within 30 days prior to enrollment; Intra-Operative Exclusion Criteria (Surgical Complications):
  • A subject with a history of complications, adverse events, trauma or disease in the nasolacrimal area, whether or not it was due to punctal plug wear, including but not limited to dacryocystitis, inflammation or canaliculitis in either eye
  • A subject with a known or suspected allergy or hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs), or to any component of the test article
  • A subject that has a condition associated with the fluctuation of hormones that could lead to refractive changes
  • A subject has a history of ocular trauma in their scheduled surgical eye
  • A subject with pupil abnormalities (non-reactive, tonic pupils, abnormally shaped pupils, or pupils that do not dilate at least 3.5 mm under mesopic/scotopic conditions) in their scheduled surgical eye
  • A subject with a history of chronic/recurrent inflammatory eye disease (e.g., scleritis, uveitis, herpes keratitis) in either eye
  • A subject with an acute or chronic disease, or illness, that would increase risk or confound study results (e.g., autoimmune disease, connective tissue disease, immunocompromised, suspected glaucoma, glaucomatous changes in the fundus or visual field, other source of ocular inflammation, etc.)
  • A subject with an uncontrolled systemic disease: A potential subject in whom therapy for a systemic disease is not yet stabilized will not be considered for entry into the study
  • A subject with diabetes that is poorly controlled
  • Floppy iris syndrome
  • A subject with any moderate to severe lid, conjunctival or corneal findings in either eye at the screening visit
  • A subject with any signs of intraocular inflammation (cells/flare) in either eye at the screening visit
  • A subject with only one eye with potentially good vision
  • A subject with amblyopia or strabismus
  • A subject with a clinically significant corneal abnormality (e.g., stromal, epithelial or endothelial dystrophies) that, in the best judgment of the investigator, is likely to interfere with the outcomes of the study
  • A subject with an inability to achieve keratometric stability for contact lens wearers
  • A subject with uncontrolled glaucoma
  • Sulcus-sulcus or bag-sulcus fixation
  • Posterior capsular rupture or zonular dialysis
  • Disruption of anterior hyaloid face
  • Vitreous loss
  • Inability to place IOL in capsular bag
  • Significant anterior chamber hyphema
  • Significant zonular rupture

Helyszínek itt: Egyesült Államok

  • Harvard Eye AssociatesLaguna Hills, Egyesült ÁllamokContact: John Hovanesian, MDToborzás még nem indult

A vizsgálatról

Mit akar kideríteni a vizsgálat

A self-controlled, prospective clinical study of the safety, clinical efficacy, and patient acceptance of subconjunctival delivery of triamcinolone 40 mg/mL (Triesence) at the conclusion of cataract surgery or topical clobetasol 0.05 (Byqlovi) BID for 14 days, with intracameral moxifloxacin 0.5%, and topical nepafenac 0.3% (Ilevro) for 14 days, as compared to traditional topical postoperative prednisolone acetate 1% QID, moxifloxacin 0.5% drops QID, and ketorolac 0.5% QID in controlling postoperative pain and inflammation in subjects undergoing sequential bilateral cataract surgery.

A vizsgálat 2 csoportja

  • Experimental GroupA vizsgált kezelés

    Triesence or Byqlovi Arm with nepafenac

    Kezelés: Triamcinolone (Optional)

  • Control GroupMár használt kezelés, összehasonlításként

    Topical Moxifloxacin, Ketorolac, Prednisolone Acetate

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
A regiszteradat frissítve
2026. március 31.